Registro exitoso
Cuenta activada - Validación pendiente.
Su cuenta se ha activado con éxito, pero aún debemos validarlo como profesional de la salud. Le enviaremos un correo electrónico con el resultado del proceso de validación en los próximos cinco días.
Mientras tanto, puedes disfrutar del contenido público en nuestro sitio web
Published Manuscripts
View free article abstracts about TRIUMEQ
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials
François Raffi, Anita Rachlisb, Cynthia Brinsonc, Keikawus Arastehd, Miguel Go´rgolase, Clare Brennanf, Keith Pappaf, Steve Almondg, Catherine Granierh, W. Garrett Nicholsf, Robert Liam Cuffei, Joseph Eron Jrj and Sharon Walmsley AIDS 2015, 29:167–174
Read the abstract>>
SINGLE study 48 weeks (treatment-naïve patients)
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1
Walmsley SL, Antela A, Clumeck N, et al, for the SINGLE investigatorsN Engl J Med 2013; 369: 1807-1818.
Read the abstract>>
SINGLE study 96 weeks and 144 weeks (treatment-naïve patients)
Dolutegravir plus abacavir/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: Week 96 and Week 144 results from the SINGLE randomized clinical trial
Sharon Walmsley, Axel Baumgarten, Juan Berenguer, Franco Felizarta, Eric Florence, Marie-Aude Khuong-Josses, J. Michael Kilby, Thomas Lutz, Daniel Podzamczer, Joaquin Portilla, Norman Roth, Deborah Wong, Catherine Granier, Brian Wynne, and Keith Pappa J Acquir Immune Defic Syndr 2015;70:515–519.
Read the abstract>>
Bioequivalence of TRIUMEQ compared with its components
Bioequivalence of a Dolutegravir, Abacavir and Lamivudine Fixed-Dose Combination Tablet and the Effect of Food
Stephen Weller, M.S., Shuguang Chen, Ph.D.,1 Julie Borland, B.S.,1 Paul Savina, M.S.,1 Brian Wynne, M.D.,2 Stephen Piscitelli, Pharm.D.1 GlaxoSmithKline, 1Research Triangle Park, NC, and 2Upper Providence, PA, USA JAIDS [In press, include citation once published]
Read the abstract>>
TRIUMEQ, TIVICAY, ZIAGEN, EPIVIR, KIVEXA, EPZICOM, TRIZIVIR, COMBIVIR
son marcas registradas del grupo de compañías ViiV Healthcare
